Skip to main content
Erschienen in: Current Cardiology Reports 5/2013

01.05.2013 | Nuclear Cardiology (V Dilsizian, Section Editor)

Is Ischemia the Most Powerful Indicator of Myocardial Viability?

verfasst von: Jamshid Shirani

Erschienen in: Current Cardiology Reports | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Chronic symptomatic ischemic heart failure remains a major cause of morbidity and mortality in the adult. Recently, the utility of coronary revascularization in early management of patients with stable ischemic heart failure has come into question by several randomized clinical trials. Some of these studies have also challenged the notion that determination of the predominant state of the dysfunctional left ventricular myocardium (viable or scarred) may facilitate identification of patients who would benefit the most from revascularization. These prospective, randomized, multi-center trials have also exposed many of the practical impediments to conducting an ideal clinical investigation particularly in the context of increasingly recognized need for goal-directed and personalized approaches to management of ischemic heart disease. This review summarizes the present evidence for an ischemia-guided approach to evaluation and treatment of chronic ischemic heart disease with left ventricular systolic dysfunction.
Literatur
1.
Zurück zum Zitat Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220.PubMedCrossRef
2.
Zurück zum Zitat Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–9.PubMedCrossRef Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–9.PubMedCrossRef
3.
Zurück zum Zitat Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22:228–36.PubMedCrossRef Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22:228–36.PubMedCrossRef
4.
Zurück zum Zitat Bart BA, Shaw LK, McCants Jr CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–8.PubMedCrossRef Bart BA, Shaw LK, McCants Jr CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–8.PubMedCrossRef
5.
Zurück zum Zitat Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210–8.PubMedCrossRef Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210–8.PubMedCrossRef
6.
Zurück zum Zitat Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail. 2011;13:528–36.PubMedCrossRef Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail. 2011;13:528–36.PubMedCrossRef
7.
Zurück zum Zitat Gheorghiade M, Flaherty JD, Fonarow GC, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol. 2011;151:69–75.PubMedCrossRef Gheorghiade M, Flaherty JD, Fonarow GC, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol. 2011;151:69–75.PubMedCrossRef
8.
Zurück zum Zitat Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRef Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRef
9.
Zurück zum Zitat Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRef Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRef
10.
Zurück zum Zitat Diamond GA, Forrester JS, de Luz PL, et al. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J. 1978;95:204–9.PubMedCrossRef Diamond GA, Forrester JS, de Luz PL, et al. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J. 1978;95:204–9.PubMedCrossRef
11.
Zurück zum Zitat Rahimtoola SH. Coronary bypass surgery for chronic angina-1981: a perspective. Circulation. 1982;65:225–41.PubMedCrossRef Rahimtoola SH. Coronary bypass surgery for chronic angina-1981: a perspective. Circulation. 1982;65:225–41.PubMedCrossRef
12.
Zurück zum Zitat Elefteriades JA, Tolis Jr G, Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411–7.PubMedCrossRef Elefteriades JA, Tolis Jr G, Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22:1411–7.PubMedCrossRef
13.
Zurück zum Zitat Baker DW, Jones RH, Hodges J, et al. Management of heart failure: III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA. 1994;272:1528–34.PubMedCrossRef Baker DW, Jones RH, Hodges J, et al. Management of heart failure: III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA. 1994;272:1528–34.PubMedCrossRef
14.
Zurück zum Zitat Appoo J, Norris C, Merali S, et al. Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation. 2004;110:II13–7.PubMedCrossRef Appoo J, Norris C, Merali S, et al. Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction. Circulation. 2004;110:II13–7.PubMedCrossRef
15.
Zurück zum Zitat Filsoufi F, Rahmanian PB, Castillo JG, et al. Results and predictors of early and late outcome of coronary artery bypass grafting in patients with severely depressed left ventricular function. Ann Thorac Surg. 2007;84:808–16.PubMedCrossRef Filsoufi F, Rahmanian PB, Castillo JG, et al. Results and predictors of early and late outcome of coronary artery bypass grafting in patients with severely depressed left ventricular function. Ann Thorac Surg. 2007;84:808–16.PubMedCrossRef
16.
Zurück zum Zitat Nardi P, Pellegrino A, Scafuri A, et al. Long-term outcome of coronary artery bypass grafting in patients with left ventricular dysfunction. Ann Thorac Surg. 2009;87:1401–7.PubMedCrossRef Nardi P, Pellegrino A, Scafuri A, et al. Long-term outcome of coronary artery bypass grafting in patients with left ventricular dysfunction. Ann Thorac Surg. 2009;87:1401–7.PubMedCrossRef
17.
Zurück zum Zitat Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail. 2011;13:773–84.PubMedCrossRef Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail. 2011;13:773–84.PubMedCrossRef
18.
Zurück zum Zitat •• Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8. This is a landmark paper that set the stage for large scale, prospective studies aimed at evaluating the relevance of noninvasive testing for myocardial viability in management of ischemic heart disease with left ventricular systolic dysfunction.PubMedCrossRef •• Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8. This is a landmark paper that set the stage for large scale, prospective studies aimed at evaluating the relevance of noninvasive testing for myocardial viability in management of ischemic heart disease with left ventricular systolic dysfunction.PubMedCrossRef
19.
Zurück zum Zitat Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410.PubMedCrossRef Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375–410.PubMedCrossRef
20.
Zurück zum Zitat Camici PH, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.PubMedCrossRef Camici PH, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117:103–14.PubMedCrossRef
21.
Zurück zum Zitat Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol. 1993;22:984–97.PubMedCrossRef Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol. 1993;22:984–97.PubMedCrossRef
22.
Zurück zum Zitat Bonow RO. Myocardial viability and prognosis in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1159–61.PubMedCrossRef Bonow RO. Myocardial viability and prognosis in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2002;39:1159–61.PubMedCrossRef
23.
Zurück zum Zitat Bourque JM, Hasselblad V, Velazquez EJ, et al. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J. 2003;146:621–7.PubMedCrossRef Bourque JM, Hasselblad V, Velazquez EJ, et al. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J. 2003;146:621–7.PubMedCrossRef
24.
Zurück zum Zitat Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.PubMedCrossRef Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.PubMedCrossRef
25.
Zurück zum Zitat Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.PubMedCrossRef Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.PubMedCrossRef
26.
Zurück zum Zitat Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularisation trial (HEART). Eur J Heart Fail. 2011;13:227–33.PubMedCrossRef Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularisation trial (HEART). Eur J Heart Fail. 2011;13:227–33.PubMedCrossRef
27.
Zurück zum Zitat D’Egidio G, Nichol G, Williams K, et al. Identification of high-risk patients with increasing ischemic cardiomyopathy. JACC Cardiovasc Imaging. 2009;2:1060–8.PubMedCrossRef D’Egidio G, Nichol G, Williams K, et al. Identification of high-risk patients with increasing ischemic cardiomyopathy. JACC Cardiovasc Imaging. 2009;2:1060–8.PubMedCrossRef
28.
Zurück zum Zitat • Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567–74. This post-hoc analysis of the PARR 2 trial highlights the significance of local expertise, access to advanced technology, and ability to incorporate imaging data into the clinical decision making process in order to prospectively examine the potential relevance of myocardial viability in management of patients with chronic ischemic heart disease.PubMedCrossRef • Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567–74. This post-hoc analysis of the PARR 2 trial highlights the significance of local expertise, access to advanced technology, and ability to incorporate imaging data into the clinical decision making process in order to prospectively examine the potential relevance of myocardial viability in management of patients with chronic ischemic heart disease.PubMedCrossRef
29.
Zurück zum Zitat Oh JK, Pellikka PA, Panza JA, et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012;25:327–36. Oh JK, Pellikka PA, Panza JA, et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012;25:327–36.
30.
Zurück zum Zitat Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2012;126:2115–24.PubMedCrossRef Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2012;126:2115–24.PubMedCrossRef
31.
Zurück zum Zitat • Schwartz L, Bertolet M, Feit F, et al. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv. 2012;5:166–73. In this post hoc analysis of the BARI 2D trial, the completeness of revascularization was examined in 751 patients who were randomly assigned to early revascularization (264 surgical and 487 percutaneous) using the residual postprocedure myocardial jeopardy index. It was noted that complete revascularization was not achieved in the majority of the patients and directly affected the adjusted event free survival over a 5.3 years follow-up period (HR 1.14; P = 0.0018).PubMedCrossRef • Schwartz L, Bertolet M, Feit F, et al. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ Cardiovasc Interv. 2012;5:166–73. In this post hoc analysis of the BARI 2D trial, the completeness of revascularization was examined in 751 patients who were randomly assigned to early revascularization (264 surgical and 487 percutaneous) using the residual postprocedure myocardial jeopardy index. It was noted that complete revascularization was not achieved in the majority of the patients and directly affected the adjusted event free survival over a 5.3 years follow-up period (HR 1.14; P = 0.0018).PubMedCrossRef
32.
Zurück zum Zitat Serruys PW, Morice M-C, Kappetein P, et al. Percutaneous coronary intervention vs coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–72.PubMedCrossRef Serruys PW, Morice M-C, Kappetein P, et al. Percutaneous coronary intervention vs coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–72.PubMedCrossRef
33.
Zurück zum Zitat Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658–69.PubMedCrossRef Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19:658–69.PubMedCrossRef
34.
Zurück zum Zitat Joshi K, Alam I, Ruben E, et al. Effect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischemic left ventricular dysfunction. Eur J Echocardiogr. 2011;12:454–560.PubMedCrossRef Joshi K, Alam I, Ruben E, et al. Effect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischemic left ventricular dysfunction. Eur J Echocardiogr. 2011;12:454–560.PubMedCrossRef
35.
Zurück zum Zitat Samady H, Eldfteriades JH, Abott BG, et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100:1298–304.PubMedCrossRef Samady H, Eldfteriades JH, Abott BG, et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100:1298–304.PubMedCrossRef
36.
Zurück zum Zitat Acampa W, Petretta M, Spinelli L, et al. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging. 2005;32:430–7.PubMedCrossRef Acampa W, Petretta M, Spinelli L, et al. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. Eur J Nucl Med Mol Imaging. 2005;32:430–7.PubMedCrossRef
37.
Zurück zum Zitat Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol. 2010;17:646–54.PubMedCrossRef Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol. 2010;17:646–54.PubMedCrossRef
38.
Zurück zum Zitat Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–43.PubMedCrossRef Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;97:535–43.PubMedCrossRef
39.
Zurück zum Zitat Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029–39.PubMedCrossRef Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029–39.PubMedCrossRef
40.
Zurück zum Zitat Lertsburapa K, Ahlberg AW, Heller GV, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium-82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15:745–53.PubMed Lertsburapa K, Ahlberg AW, Heller GV, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium-82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15:745–53.PubMed
41.
Zurück zum Zitat Dorbala S, Hachamovitch R, Kwong RY, Di Carli MF. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:846–54.CrossRef Dorbala S, Hachamovitch R, Kwong RY, Di Carli MF. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:846–54.CrossRef
42.
Zurück zum Zitat Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion singly photon emission computed tomography. Circulation. 2003;107:2900–7.PubMedCrossRef Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion singly photon emission computed tomography. Circulation. 2003;107:2900–7.PubMedCrossRef
43.
Zurück zum Zitat Herzog BA, Husmann L, Kaufmann PA, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion PET: added value of coronary flow reserve. J Am Coll Cardiol. 2009;54:150–6.PubMedCrossRef Herzog BA, Husmann L, Kaufmann PA, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion PET: added value of coronary flow reserve. J Am Coll Cardiol. 2009;54:150–6.PubMedCrossRef
44.
Zurück zum Zitat Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58:740–8.PubMedCrossRef Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58:740–8.PubMedCrossRef
45.
Zurück zum Zitat Murthy VL, Carli D. Noninvasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease. J Nucl Cardiol Circ. 2011;124:2215–24. Murthy VL, Carli D. Noninvasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease. J Nucl Cardiol Circ. 2011;124:2215–24.
46.
Zurück zum Zitat •• Bingham SE, Hachamovitch R. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over pre-imaging information for the prediction of adverse events. Circulation. 2011;123:1509–18. This important study has demonstrated that noninvasive assessment of myocardial viability and stress perfusion data (normal, scar, viable, and ischemic myocardium) can provide significant incremental prognostic information in patients with suspected coronary artery disease over a mean follow up period of 2.6 years.PubMedCrossRef •• Bingham SE, Hachamovitch R. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over pre-imaging information for the prediction of adverse events. Circulation. 2011;123:1509–18. This important study has demonstrated that noninvasive assessment of myocardial viability and stress perfusion data (normal, scar, viable, and ischemic myocardium) can provide significant incremental prognostic information in patients with suspected coronary artery disease over a mean follow up period of 2.6 years.PubMedCrossRef
47.
Zurück zum Zitat Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37:81–8.PubMedCrossRef Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37:81–8.PubMedCrossRef
48.
Zurück zum Zitat Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.PubMedCrossRef Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.PubMedCrossRef
49.
Zurück zum Zitat Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529–40.PubMedCrossRef Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529–40.PubMedCrossRef
50.
Zurück zum Zitat Hochman JS, Reynolds HR, Dzavík V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011;124:2320–8.PubMedCrossRef Hochman JS, Reynolds HR, Dzavík V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011;124:2320–8.PubMedCrossRef
51.
Zurück zum Zitat Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–16.PubMedCrossRef Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–16.PubMedCrossRef
52.
Zurück zum Zitat Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.PubMedCrossRef Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.PubMedCrossRef
53.
Zurück zum Zitat Udelson JE, Pearte CA, Kimmelstiel CD, et al. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention vs optimal medical therapy alone. Am Heart J. 2011;161:611–21.PubMedCrossRef Udelson JE, Pearte CA, Kimmelstiel CD, et al. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention vs optimal medical therapy alone. Am Heart J. 2011;161:611–21.PubMedCrossRef
54.
Zurück zum Zitat Meijboom WB, Mieghem CA, Pelt N, et al. Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography vs conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol. 2008;52:636–43.PubMedCrossRef Meijboom WB, Mieghem CA, Pelt N, et al. Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography vs conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol. 2008;52:636–43.PubMedCrossRef
Metadaten
Titel
Is Ischemia the Most Powerful Indicator of Myocardial Viability?
verfasst von
Jamshid Shirani
Publikationsdatum
01.05.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 5/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0354-6

Weitere Artikel der Ausgabe 5/2013

Current Cardiology Reports 5/2013 Zur Ausgabe

Peripheral Vascular Disease (M Shishehbor, Section Editor)

Current State of Endovascular Treatment for Vasculogenic Erectile Dysfunction

Ischemic Heart Disease (D Mukherjee, Section Editor)

Cigarette Smoking and Clopidogrel Interaction

Congestive Heart Failure (J Lindenfeld, Section Editor)

Cardiac Toxicity of Anticancer Agents

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.